Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12619000375156
ACTRN12619000375156
Completed
Phase 1

A randomised, controlled phase 1 study to investigate the safety and efficacy of orally administered squalamine in subjects with Motor Neuron Disease

Wesley Medical Research0 sites12 target enrollmentMarch 11, 2019
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsMotor Neuron DiseaseNeurological - Neurodegenerative diseases

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Motor Neuron Disease
Sponsor
Wesley Medical Research
Enrollment
12
Status
Completed
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 11, 2019
End Date
November 19, 2019
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Clinically definite or clinically probable MND defined according to the revised El Escorial criteria
  • •\-Age \>18 years
  • •\-Provision of informed consent from the patient
  • •\-Willingness to give written informed consent and willingness to comply with the study

Exclusion Criteria

  • •\-Inability of patient to provide consent
  • •\-Inability to swallow capsules
  • •\-Participation in another/other clinical trials
  • •\-Prohibited concomitant medications: antibiotics, probiotics

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A Phase I study to assess Reactogenicity, safety and immunogenicity of Biological E’s Liquid Hexavalent Vaccine when administered in healthy children of 16 to 24 months.Health Condition 1: Z23- Encounter for immunization
CTRI/2023/05/052319Biological E.Limited48
Not yet recruiting
Not Applicable
A mobile health application for people in remote and rural Queensland who have experienced a cardiovascular event.Cardiovascular diseaseCoronary Heart DiseaseCardiovascular - Coronary heart disease
ACTRN12621001229864Menzies Health Institute Queensland (MHIQ)60
Active, not recruiting
Phase 1
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adults
EUCTR2020-004741-37-BEGlaxoSmithKline Biologicals1,258
Active, not recruiting
Phase 1
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adultsHealthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2020-004741-37-FIGlaxoSmithKline Biologicals1,379
Active, not recruiting
Phase 1
A study on the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine in healthy adolescents and adultsHealthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y)Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]
EUCTR2020-004741-37-PLGlaxoSmithKline Biologicals1,379